Healthcare
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, September 08, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
About this update from Neurogene Inc.
NEW YORK, September 08, 2026 --( BUSINESS WIRE )--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, September 15 at 1:00 p.m. ET A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's website under events , where a replay of the event will also be available for a limited time. About Neurogene Neurogene (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on LinkedIn . View source version on businesswire.com: https://www.businesswire.com/news/home/20260908572577/en/ Contacts Media Contact: Mike Devine Executive Director, Corporate Communications [email protected] Investor Contact: Lina Li Executive Director, Investor Relations [email protected]